adults: a cross-sectional survey based on NHANES Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang BMC Cardiovascular Disorders.2026;[Epub] CrossRef Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGERAGENF-B-mediated cytotoxicity and inflammation in diabetic kidney disease Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A
The FLOW trial was stopped early because the kidney benefit was already clear, a rare and meaningful signal
doi: 10.1080/09513590.2022.2089106 78 HeidariHHajhashemyZSaneeiP
The most commonly reported adverse events in combination groups were nausea, vomiting, and constipation